458,946 Shares in Oruka Therapeutics, Inc. $ORKA Acquired by Synergy Asset Management LLC

Key Points

• Synergy Asset Management acquired 458,946 shares of Oruka Therapeutics (~$13.91 million) in Q4, making ORKA about 1.4% of Synergy’s portfolio and leaving Synergy with a 0.95% ownership stake at quarter-end.
• Insiders have been selling23,765 shares (~$849,575) in the last three months while retaining 24.69% ownership.
• Analyst sentiment is broadly positive, with ten Buy ratings vs. one Sell, a consensus “Moderate Buy” and an average target of $59.60; notable moves include Leerink raising its target to $86 and UBS initiating coverage with a $50 Buy.

Synergy Asset Management LLC acquired a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 458,946 shares of the company's stock, valued at approximately $13,911,000. Oruka Therapeutics makes up about 1.4% of Synergy Asset Management LLC's investment portfolio, making the stock its 17th largest position. Synergy Asset Management LLC owned 0.95% of Oruka Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of ORKA. Viking Global Investors LP purchased a new stake in Oruka Therapeutics during the 3rd quarter valued at about $51,280,000. Avoro Capital Advisors LLC purchased a new stake in shares of Oruka Therapeutics in the third quarter valued at approximately $25,640,000. Deep Track Capital LP increased its holdings in shares of Oruka Therapeutics by 38.4% in the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company's stock valued at $51,051,000 after purchasing an additional 735,983 shares during the last quarter. Geode Capital Management LLC lifted its position in Oruka Therapeutics by 100.6% during the second quarter. Geode Capital Management LLC now owns 707,406 shares of the company's stock worth $7,932,000 after buying an additional 354,821 shares in the last quarter. Finally, Commodore Capital LP boosted its stake in Oruka Therapeutics by 23.5% during the third quarter. Commodore Capital LP now owns 1,753,054 shares of the company's stock worth $33,711,000 after buying an additional 333,340 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Oruka Therapeutics news, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $41.30, for a total value of $71,407.70. Following the completion of the transaction, the chief executive officer directly owned 927,309 shares of the company's stock, valued at $38,297,861.70. The trade was a 0.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Joana Goncalves sold 7,641 shares of the business's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $40.91, for a total transaction of $312,593.31. Following the sale, the insider owned 33,377 shares in the company, valued at $1,365,453.07. This trade represents a 18.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 23,765 shares of company stock worth $849,575. 24.69% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ORKA has been the subject of a number of recent research reports. Leerink Partners raised their target price on Oruka Therapeutics from $58.00 to $86.00 and gave the stock an "outperform" rating in a research note on Monday, March 16th. Weiss Ratings restated a "sell (d-)" rating on shares of Oruka Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen raised shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, March 16th. UBS Group started coverage on shares of Oruka Therapeutics in a report on Wednesday, January 7th. They set a "buy" rating and a $50.00 price target for the company. Finally, Wedbush reiterated an "outperform" rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research report on Friday, March 13th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $59.60.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $45.46 on Friday. The company's 50 day simple moving average is $35.12 and its 200-day simple moving average is $29.13. Oruka Therapeutics, Inc. has a 1 year low of $5.49 and a 1 year high of $47.25. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of -24.44 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.16. Equities analysts expect that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.